General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iv.iiarjournals.org

Selection of Recent Articles

- Proteomic Profiling to Identify Prognostic Biomarkers in Heart Failure. P.A. SCOTT, B. ZEIDAN, L.L. NG, M. ZEB, J.A. ROSENGARTEN, S. GARBI, N.P. CURZEN, J.M. MORGAN, P.A. TOWNSEND (Southampton; Leicester, UK; Athens, Greece)
- Diverging In Vitro Antibody Isotype Switching Preference in B-Lymphocytes from C57BL/6 and FVB Mice. A.G. PUTHIYAVEETIL, B. OKYERE, C.M. REILLY, D. CAUDELL (Blacksburg, VA, USA)
- The Zebrafish – Danio rerio – Is a Useful Model for Measuring the Effects of Small-molecule Mitigators of Late Effects of Ionizing Irradiation. M.W. EPPERLY, N. BAHARY, M. QUADER, V. DEWALD, J.S. GREENBERGER (Pittsburgh, PA, USA)
- Breast Cancer: Mechanisms Involved in Action of Phytoestrogens and Epigenetic Changes. A. DAGDEMIR, J. DURIF, M. NGOLLO, Y.-J. BIGNON, D. BERNARD-GALLON (Clermont-Ferrand, France)
- Positron-emission Tomography (PET) Imaging Agents for Diagnosis of Human Prostate Cancer: Agonist vs. Antagonist Ligands. P.K. NANDA, B.E. WIENHOFF, T.L. ROLD, G.L. SIEGRUM, T.J. HOFFMAN, B.E. ROGERS, C.J. SMITH (Columbia; St. Louis, MO, USA)
- In Vivo Models for Defining Molecular Subtypes of the Primitive Neuroectodermal Tumor Genome: Current Challenges and Solutions. J.D. LARSON, D.A. LARGAESPADA (Minneapolis, MN, USA)
- Effects of Minocycline on Hematopoietic Recovery After Whole-body Irradiation. S. MEHROTRA, M.J. PECAUT, D.S. GRIDLEY (Loma Linda, CA, USA)
- Sequential Changes in the Expression of Wnt- and Notch-related Genes in the Vagina and Uterus of Ovariectomized Mice after Estrogen Exposure. T. NAKAMURA, S. MIYAGAWA, Y. KATSU, T. SATO, T. IGUCHI, Y. OHTA (Yamagata; Okazaki; Sapporo; Yokohama; Tottori, Japan)
- Catecholamines Reduce Dose-dependent Oedema Formation and Inflammatory Reaction in an Isolated Rat Lung Model. C. DACHO, A. DACHO, A. GEISSLER, C. HAUSER, K. NOWAK, G. BECK (Heidelberg; Essen; Wiesbaden, Germany)
- Biocompatibility of Membranes with Unrestricted Somatic Stem Cells. C. NAUJOKS, F.P. VON BECK, F. LANGENBACH, M. BORGGREFE, D. HAGHI, J. SAUR (Mannheim, Germany)
- Acclimatization of Mice to Different Cage Types and Social Groupings with Respect to Fecal Secretion of IgA and Corticosterone Metabolites. C.J. BUNDGAARD, O. KALLIOKOSKI, K.S. ABELSON, J. HAU (Copenhagen, Denmark)
- Exploring Anticarcinogenic Agents in a Rat Hepatocarcinogenesis Model – Focus on Selenium and Statins. L. BJÖRKHEM-BERGMAN, L. EKSTRÖM,L.C. ERIKSSON (Stockholm, Sweden)
- Amino Acid Chloramine Damage to Proliferating Cell Nuclear Antigen in Mammalian Cells. S.A. SALAMA, R.M. SNAPKA (Columbus, OH, USA; Cairo, Egypt)

The Effect of Insulin-like Growth Factor II in the Regulation of Tumour Cell Growth In Vitro and Tumourigenesis In Vivo. M. HALJÉ, M. NORDIN, D. BERGMAN, W. ENGSTRÖM (Uppsala, Sweden)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST
Instructions to Authors 2013

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2013 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Importance of FOXP3 in Prognosis and Its Relationship with p16 in Tonsillar Squamous Cell Carcinoma. K. PARK, K.J. CHO, M. LEE, D.H. YOON, S.-B. KIM (Seoul, Republic of Korea) ................................................................. 5667

Analysis of Intrafractional Organ Motion for Patients with Prostate Cancer Using Soft Tissue Matching Image-guided Intensity-modulated Radiation Therapy by Helical Tomotherapy. K. IWAMA, H. YAMAZAKI, T. NISHIMURA, Y. OOTA, H. AIBE, S. NAKAMURA, H. IKENO, K. YOSHIDA, H. OKABE (Uji; Kyoto, Kyoto; Takatsuki, Osaka, Japan) ......................................................... 5675

Post-transplantation Consolidation and Maintenance Therapy with Lenalidomide for Japanese Patients with Multiple Myeloma. H. TAKAMATSU, S. MUNEMOTO, R. MURATA, Y. TERASAKI, K. NAKAJIMA, S. NAKAO (Kanazawa; Toyama, Japan) .................................................. 5681

Re-irradiation Using Interstitial Brachytherapy Increases Vaginal Mucosal Reaction Compared to Initial Brachytherapy in Patients with Gynecological Cancer. K. YOSHIDA, H. YAMAZAKI, S. NAKAMURA, K. MASUI, T. KOTSUMA, H. AKIYAMA, E. TANAKA, Y. YOSHIOKA (Takatsuki; Osaka; Suita, Osaka; Kyoto, Kyoto, Japan) .............................................................. 5687


Phase I Pharmacokinetic Study of S-1 Granules and Nedaplatin for Advanced Head and Neck Cancer. H. HAYASHI, I. OKAMOTO, S. UEDA, K. TANAKA, K. OKAMOTO, H. KAWAKAMI, S. NISHINA, M. TAKEDA, Y. FUJISAKA, T. SATOH, K. TERAO, Y. NISHIMURA, K. DOI, K. NAKAGAWA (Osaka; Suita; Takatsuki, Osaka; Kishiwa; Fukuoka, Japan) ................................................................. 5699

Errata .................................................................................................................................................. 5707

Book Reviews ...................................................................................................................................... 5709

Announcements ................................................................................................................................... 5712
Usefulness of $^{18}$F-fluorodeoxyglucose Positron Emission Tomography as Predictor of Distant Metastasis in Preoperative Carbon-ion Radiotherapy for Pancreatic Cancer. M. SHINOTO, S. YAMADA, K. YOSHIKAWA, S. YASUDA, Y. SHIOYAMA, H. HONDA, T. KAMADA, H. TSUJI (Tosu, Saga; Chiba, Chiba; Fukuoka, Kyushu, Japan) .......................................................... 5579


C-reactive Protein as a Significant Prognostic Factor for Stage IV Gastric Cancer Patients. H. BABA, K. KUWABARA, T. ISHIHGURO, S. HATANO, T. MATSUZAWA, M. FUKUCHI, Y. KUMAGAI, K. ISHIBASHI, E. MOCHIKI, H. ISHIDA (Saitama, Japan) .......................................................... 5591

Chemotherapy Followed by Surgery on the Basis of Biomarker Examination for Patients with Advanced Non-small Cell Lung Cancer. H. YOKOMISE, D. LIU, S. ISHIKAWA, T. GO, M. GOTOH, M. OKUDA, S. TARUMI, Y. KASAI, N. MATSUURA (Kagawa, Japan) .......................................................... 5597

Efficacy of Transcatheter Arterial Chemoembolization with Miriplatin–Lipiodol Water-soluble Contrast Agent Emulsion in Patients with Hepatocellular Carcinoma. K. OKIMOTO, S. OGASAWARA, T. CHIBA, Y. OOKA, M. OOBU, R. AZEMOTO, N. KANOGAWA, T. MOTOYAMA, E. SUZUKI, A. TAWADA, M. YOSHIKAWA, O. YOKOSUKA (Chiba; Kisarazu, Chiba, Japan) .......................................................... 5603

Immunopositivity of Beclin-1 and ATG5 as Indicators of Survival and Disease Recurrence in Oral Squamous Cell Carcinoma. J.-Y. TANG, Y.-Y. FANG, E. HSI, Y.-C. HUANG, N.C.-H. HSU, W.-C. YANG, H.-W. CHANG, C.-Y. CHAI, P.-Y. CHU (Kaohsiung; Chiayi; New Taipei City, Taiwan, ROC) .......................................................... 5611


Long-term Outcome in Patients with Recurrent Malignant Glioma Treated with Perillyl Alcohol Inhalation. C.O. DA FONSECA, R.M. TEIXEIRA, J.C.T. SILVA, J. DE SALDANHA DA GAMA FISCHER, O.C. MEIRELLES, J.A. LANDEIRO, T. QUIRICO-SANTOS (Niteroi; Ipanema; Rio de Janeiro, RJ; Curitiba, PR, Brazil) .......................................................... 5625


Cancer Treatment of Severely-III Patients Not Eligible for Chemotherapy. M. RANDÉN, S. RUNESDOTTER, P. STRANG (Stockholm, Sweden) .......................................................... 5639

Patients with Brain Metastases from Colorectal Cancer Are Not Condemned. D. MEGE, M. OUAISSI, D. FUKS, P. METELLUS, J. PELTIER, H. DUFOUR, J.-M. REGIMBEAU, L. DAHAN, I. SIELEZNEFF, B. SASTRE (Marseille; Amiens, France) .......................................................... 5645


A Higher Body Mass Index and Fat Mass Are Factors Predictive of Docetaxel Dose Intensity. S. GOUÉRANT, M. LEHERUETEUR, M. CHAKER, R. MODZELEWSKI, O. RIGAL, C. VEYRET, G. LAURIDANT, F. CLATOT (Rouen; Caen; Lille, France) .......................................................... 5655

Contents continued on the preceding page
Factors Predictive of Oncological Outcome After Nephroureterectomy: Comparison Between Laparoscopic and Open Procedures. K. IZUMI, S. ITAI, Y. TAKAHASHI, R. TAKAHASHI, A. MAOLAKE, M. OFUDE, S. UENO, Y. KADONO, Y. KITAGAWA, H. KONAKA, A. MIZOKAMI, M. NAMIKI (Kanazawa, Japan) ........................................ 5501

Exceptionally High Incidence of Grade 2-3 Late Rectal Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft Tissue-matched Image-guided Intensity-modulated Radiotherapy. T. NISHIMURA, H. YAMAZAKI, N. AIBE, S. NAKAMURA, K. YOSHIDA, H. OKABE (Uji: Kyoto; Takatsuki, Osaka, Japan) ................................................................. 5507


Gemcitabine for the Treatment of Classic Kaposi’s Sarcoma: A Case Series. F. ZUSTOVICH, A. FERRO, S. TOSO (Padua; Adria, Italy) .......................................................... 5531

Phase II trial of Pemetrexed Continuation – Maintenance after Carboplatin-based Induction in Untreated Non-squamous Non-small Cell Lung Cancer. S. MINAMI, T. KIJIMA, K. KOMUTA, M. SHIBATA, S. YOKOTA, Y. TAKEUCHI, T. NAKATANI, I. TACHIBANA, I. KAWASE (Osaka; Suita; Toyonaka, Osaka, Japan) .......................................................... 5535

Quality of Life Assessment in Taiwanese Patients with Bone Metastases from Breast Cancer Receiving Zoledronic Acid. T.-C. CHAO, D.-R. CHEN, T.-Y. CHAO, S.-C. CHEN, D.-C. YEH, H.-C. WANG, W.-T. HUANG, K.-M. RAU, K.-J. CHANG, T.-L. YANG, K.-D. LEE, C.-J. TAI, L.-M. TSENG, M.-F. HOU (Taipei; Changhua; New Taipei City; Taichung; Kaohsiung; Chiayi, Taiwan, ROC) .......................................................... 5543

Improvement of Adherence to Guidelines for Antiemetic Medication Enhances Emetic Control in Patients with Colorectal Cancer Receiving Chemotherapy of Moderate Emetic Risk. H. FUJII, H. IIHARA, M. ISHIHARA, T. TAKAHASHI, K. YOSHIDA, Y. ITOH (Gifu, Japan) .......................................................... 5549

Octreotide Acetate–Steroid Combination Therapy for Malignant Gastrointestinal Obstruction. H. MURAKAMI, H. MATSUMOTO, M. NAKAMURA, T. HIRAI, Y. YAMAGUCHI (Okayama, Japan) .......................................................... 5557

Non-surgical Multimodality Treatment for Locally Advanced (T3-4) Hypopharyngeal Cancer: The Impact of Pre-treatment Hemoglobin Level. G. SUZUKI, E. OGO, T. ABE, N. HAYABUCHI, H. UMENO, T. NAKASHIMA, H. YAMAZAKI, S. NAKAMURA, K. YOSHIDA (Kurume, Fukuoka, Japan; Kyoto; Takatsuki, Osaka, Japan) .......................................................... 5561


A Novel Chemotherapeutic Arene Ruthenium(II) Drug Rawq01 Altered the Effect of microRNA-21 on PTEN/AKT Signaling Pathway in Esophageal Cancer Cells. W. WENG, Q. WU, Y. YU, W. MEI, X. WANG (Shanghai; Guangzhou; Beijing, PR China) ........................................................................... 5407


Evaluation of Stem Cell Marker Gene Expression in Canine Prostate Carcinoma- and Prostate Cyst-derived Cell Lines. M. MOULAY, W. LIU, S. WILLENBROCK, K.A. STERENCZAK, R. CARLSON, A. NGEZAHIKO, H.M. ESCOBAR, I. NOLTE (Hannover; Rostock, Germany) ........................................................................... 5421

Acquired Resistance to Chemotherapy in Lung Cancer Cells Mediated by Prolonged Nitric Oxide Exposure. P. WONGVARANON, V. PONGRAKHANANON, P. CHUNHACHA, P. CHANVORACHOTE (Bangkok, Thailand) ........................................................................... 5433


Antibody Against Tumor Necrosis Factor-α Reduces Bortezomib-induced Allodynia in a Rat Model. A. CHIORAZZI, A. CANTA, C. MEREGALI, V. CAROZZI, B. SALA, N. OGGIONI, J. MONBALI, H. VAN DE VELDE, G. CAVALETTI (Monza, Italy; Beerse, Belgium) ........................................................................... 5453

Epithelial-mesenchymal Transition and Cancer Stem Cells in Endometrial Cancer. A. SUPERNAT, S. ŁAPIŃSKA-SZUMCZYK, H. MAJEWSKA, J. GULCZYŃSKI, W. BIERNAT, D. WYDRA, A.J. ŻACZEK (Gdańsk, Poland) ........................................................................... 5461

Clinical Studies

Advanced Microtubular Colorectal Adenomas: A 10-Year Survey at a Single Hospital. C.A. RUBIO, E. JARAMILLO (Stockholm, Sweden) ........................................................................... 5471

An ELCWP Phase III Trial Comparing Ifosfamide and Cisplatin Regimens in Advanced NSCLC. T. BERGHMAN, J.-J. LAFITTE, A. SCHERPREEEL, M. PAESMANS, J. LECOMTE, V. GINES MARCO, A.-P. MEERT, N. LECLERCQ, J.-P. SCULIER for The European Lung Cancer Working Party (Brussels; Charleroi, Belgium; Lille, France; Valencia, Spain) ........................................................................... 5477

Levels of Circulating Polychlorinated Biphenyls and Mammographic Breast Density. C. DIORIO, I. DUMAS, T.M. SANDANGER, P. AYOTTE (Quebec City, QC, Canada; Tromsø, Norway) ........................................................................... 5483

Disease Outcome of Patients with Pancreatic Cancer in a Cohort Treated Outside Clinical Trials. H.M. KOSKELA, K. SYRJÄNEN, E.A. KORKEILA (Turku; Helsinki, Finland; Sao Paolo, Brazil) ........................................................................... 5491

Wilms’ Tumor Gene 1 (WT1) – loaded Dendritic Cell Immunotherapy in Patients with Uterine Tumors: A Phase II/II Clinical Trial. A. COOSEMANS, A. VANDESTRAETEN, S. TUYAERTS, T. VERSCHUERE, P. MOERMAN, Z.N. BERNEKAN, I. VERGOTE, F. AMANT, S.W. VAN GOOL (Leuven; Antwerp, Belgium) ........................................................................... 5495

Contents continued on the preceding page
Activation of DNA Damage Response by Antitumor Therapy Counteracts the Activity of Vinca Alkaloids. H. EHRHARDT, S. PFEIFFER, D. SCHREMS, F. WACHTER, M. GRUNERT, I. JEREMIAS (Munich, Germany) 

Expression of mRNAs of Urocortin in the STKM-1 Gastric Cancer Cell Line. K. AKIYOSHI, M. KAMADA, K. FUJIOKA, K. IKEDA, K. TOJO, Y. MANOME (Tokyo, Japan) 

Zoledronic Acid as an Antimetastatic Agent for Different Human Tumor Cell Lines. L. MUINELO-ROMAY, D. GARCIA, L. ALONSO-ALCONADA, M. VIEITO, M. CARMONA, N. MARTÍNEZ, S. AGUÍN, M. ABAL, R. LÓPEZ-LOPEZ (Santiago de Compostela, Spain) 

Silicate Fiber-based 3D Cell Culture System for Anticancer Drug Screening. Y. YAMAGUCHI, D. DENG, Y. SATO, Y.-T. HOU, R. WATANABE, K. SASAKI, M. KAWABE, E. HIRANO, T. MORINAGA (Kurume, Fukuoka; Koga, Ibaraki, Japan) 

Prokineticin 1 Expression in Gastrointestinal Tumors. T. GOI, T. NAKAZAWA, Y. HIRONO, A. YAMAGUCHI (Fukui, Japan) 

Regulations of ABCB1 and ABCG2 Expression Through MAPK Pathways in Acute Lymphoblastic Leukemia Cell Lines. H. TOMIYASU, M. WATANABE, K. SUKITA, Y. GOTO-KOSHINO, Y. FUJINO, K. OHNO, S. SUGANO, H. TSUJIMOTO (Tokyo; Chuo, Yamanashi, Japan) 

Green Tea Polyphenol Epigallocatechin 3-Gallate, Contributes to the Degradation of DNMT3A and HDAC3 in HCT 116 Human Colon Cancer Cells. V.R. MOSELEY, J. MORRIS, R.W. KNACKSTEDT, M.J. WARGOVICH (Charleston, SC; San Antonio, TX, USA) 


EGFRvIII – A Stable Target for Anti-EGFRvIII Therapy. M. BANASZCZYK, E. STOCHYNSKA-FIDELUS, M. WINIECKA-KLIMEK, M. BIENKOWSKI, W. OCH, P. RIESKE, S. PIASKOWSKI (Lodz; Olsztyn, Poland) 

Dichamanetin Inhibits Cancer Cell Growth by Affecting ROS-related Signaling Components Through Mitochondrial-mediated Apoptosis. Y. YONG, S. MATTHEW, J. WITTWER, L. PAN, Q. SHEN, A.D. KINGHORN, S.M. SWANSON, E.J. DE BLANCO (Columbus, OH; Chicago, IL, USA) 


Suppression of OCT4B Enhances Sensitivity of Lung Adenocarcinoma A549 Cells to Cisplatin via Increased Apoptosis. L. CORTES-DERICKS, E. FARASHAHI YAZD, S.J. MOWLA, R.A. SCHMID, G. KAROUBI (Berna, Switzerland; Tehran; Yazd, Iran) 

Comparison of Minichromosome Maintenance Proteins (MCM-3, MCM-7) and Metallothioneins (MT-I/II, MT-III) Expression in Relation to Clinicopathological Data in Ovarian Cancer. C. KOBIERZYCKI, B. PULA, M. SKIBA, K. JABLONSKA, K. LATKOWSKI, M. ZABEL, E. NOWAK-MARKWITZ, M. SPACZYNSKI, W. KĘDZIA, M. PODHORSKA-OKOLOW, P. DZIEGIEL (Wroclaw; Poznan, Poland) 